HIMS Hims & Hers Health, Inc. stock chart & analysis
Conviction 36HealthcareScan · Tue, Nov 10, 2026Hims & Hers Health, Inc. (HIMS) closed at $19.14 (-16.56%) on Nov 10, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 30, RS Rating 14, -55.2% from its 52-week high, -41.0% year to date. Sector: Healthcare · Services-Offices & Clinics of Doctors of Medicine.
Financials as of Wed, Sep 30, 2026 · quarterly.
HIMS technical analysis
Trend
HIMS's moving averages are mixed — no clean uptrend or downtrend. It closed 31.9% below the 50-day ($28.10) and 28.6% below the 200-day ($26.82). ADX(14) at 18 points to a weak trend — more range than direction. It meets 2 of 8 trend-template criteria.
Momentum
RSI(14) is 30, in oversold territory. MACD crossed below its signal line 7 sessions ago. A bullish RSI divergence is in place. Its RS Rating of 14 puts its weighted 12-month performance ahead of about 14% of the US market.
Volume and volatility
Volume on the latest session ran 4.0× its 20-day average. It trades about $359.4M a day on average. ATR(14) is $2.33, 12.2% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.29) shows distribution.
Key levels
The chart pattern's support is $25.74 and its resistance $31.80. The 52-week range is $13.74 to $42.70; price is 55.2% below the high and 39.3% above the low. The VWAP anchored at the 52-week high is $26.86, above price.
Performance
HIMS returned -25.5% (1 week), -37.5% (1 month), -36.1% (3 months), -23.5% (6 months), -53.3% (1 year), -41.0% (year to date).
About Hims & Hers Health, Inc.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Services-Offices & Clinics of Doctors of Medicine · Listed 2021 · 2,442 employees
Recent news
- HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month LowsStocktwits · Tue, Nov 10, 2026
- Hims & Hers stock sinks after Q3 results, outlook disappointsYahoo Finance · Tue, Nov 10, 2026
- Hims & Hers cuts 2026 earnings outlook despite 49% revenue growthProactiveinvestors · Tue, Nov 10, 2026
- Hims & Hers Stock Plunges as Profit Vanishes and Growth Engine SputtersYahoo Finance · Tue, Nov 10, 2026
- Hims & Hers Sinks 9% on EBITDA Guidance Cut as CEO Says He’d Take Subscriber Losses “Every Time”Tikr · Tue, Nov 10, 2026
- Hims & Hers Stock Plunges Despite 49% Revenue SurgeYahoo Finance · Tue, Nov 10, 2026
- Premarket movers: Sanmina, AAON surge; Hims & Hers, Rocket Lab fallYahoo Finance · Tue, Nov 10, 2026
- Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He’ll Make ‘Every Time’247Wallst · Tue, Nov 10, 2026
- Hims & Hers: 3 Key Takeaways for Long-Term InvestorsMotley Fool · Tue, Nov 10, 2026
- JPMorgan cuts Hims and Hers stock price target on subscriber decline By Investing.comInvesting.com India · Tue, Nov 10, 2026
Congress activity
Disclosed STOCK Act trades in HIMS · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Lisa McClain house · R · MI · traded 2025-08-04 | Buy | $1K–$15K | 2025-08-04 | 2025-09-12 |
Insider activity
SEC Form 4 transactions in HIMS · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Boughton Soleil Chief Legal Officer · Class A Common Stock · 2026-10-28 | Sell | 3.46K | $96K | 2026-10-28 | 2026-10-29 |
Boughton Soleil Chief Legal Officer · Class A Common Stock · 2026-10-14 | Sell | 3.46K | $101K | 2026-10-14 | 2026-10-15 |
Okupe Oluyemi Chief Financial Officer · Class A Common Stock · 2026-09-22 | Exercise | 14K | $70K | 2026-09-22 | 2026-09-23 |
Okupe Oluyemi Chief Financial Officer · Class A Common Stock · 2026-09-22 | Sell | 29.28K | $877K | 2026-09-22 | 2026-09-23 |
Okupe Oluyemi Chief Financial Officer · Stock Option (right to buy) · 2026-09-22 | Exercise | 14K | — | 2026-09-22 | 2026-09-23 |
Boughton Soleil Chief Legal Officer · Class A Common Stock · 2026-09-16 | Sell | 6.24K | $174K | 2026-09-16 | 2026-09-17 |
Chi Michael Chief Operating Officer · Class A Common Stock · 2026-09-15 | Sell | 14.03K | $398K | 2026-09-15 | 2026-09-17 |
Elshenawy Mohamed CTO · Class A Common Stock · 2026-09-15 | Sell | 7.95K | $226K | 2026-09-15 | 2026-09-17 |
Dudum Andrew Chief Executive Officer · Class A Common Stock · 2026-08-27 | Dispose | 977.57K | — | 2026-08-27 | 2026-08-27 |
Dudum Andrew Chief Executive Officer · Class A Common Stock · 2026-08-25 | Gift | 463.29K | — | 2026-08-25 | 2026-08-27 |
SEC filings
EDGAR filings in HIMS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.